Acucela Hires Dr. Lukas Scheibler as Executive Vice President of Translational Medicine

SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced today that it has hired Dr. Lukas Scheibler as Executive Vice President of Translational Medicine. Dr. Scheibler joins Acucela after a 13-year career in research and development, business development and clinica


OSN Europe: Is monovision with monofocal IOLs a viable alternative to multifocal IOLs?

My personal preference is to use modest monovision with monofocal IOLs as an alternative to multifocal IOLs to reduce patient dependency on spectacles for near vision after cataract surgery.Although higher levels of myopic defocus provide a greater level of spectacle independence, a target of –1.25 sphere is preferred. This level of anisometropia preserves stereoacuity and is less likely to be associated with a reduction in binocular contrast sensitivity. Furthermore, this provides patients with an extended range of clear vision from distance to near, although additional correction may occasionally be required (Read more...)